
Temozolomide Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets and Oral Capsules
Available Strengths: Capsules: 5 mg, 20 mg, 100 mg, 140 mg; Tablets: 250 mg
Reference Brands: Temodar® (US & EU)
Category: Oncology Cancer Care
Temozolomide is available in Oral Tablets and Oral Capsules and strengths such as Capsules: 5 mg, 20 mg, 100 mg, 140 mg; Tablets: 250 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Temozolomide is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
Technical Specifications & Supply Details | |
---|---|
Lead Time | 7 to 60 days (depending on batch size & schedule) |
MOQ | As per manufacturer’s batch size |
COA | Available with every batch |
Regulatory Dossier / DMF | Available upon request |
Export Documentation | FSC, COA, Manufacturing License, Product Permission |
Standards | IP, BP, USP |
Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Temozolomide can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Temozolomide is an oral chemotherapy agent used in the treatment of glioblastoma multiforme (GBM) and anaplastic astrocytoma, two aggressive brain cancers. Temozolomide works by damaging cancer cell DNA, preventing replication and inducing cell death. Available in 5 mg, 20 mg, 100 mg, 140 mg, and 250 mg strengths, it is marketed under the brand name Temodar® by Merck in both the US and EU. Manufactured under GMP-compliant facilities, it offers a reliable treatment option for oncology-focused pharmaceutical partners, providing a vital oral chemotherapy solution in the global cancer treatment market.
Frequently Asked Questions
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View DetailsDurvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View DetailsSunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers